These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4587820)

  • 21. [Experimental study of a new biological preparation for treating E. coli infection and Proteus dysbacteriosis in young infants].
    Soboleva SV; Mineeva LD; Rabinovich VD; Fedorova TA
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Aug; (8):7-11. PubMed ID: 2686305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preputial condition and urinary tract infections.
    Kim KK
    J Korean Med Sci; 1996 Aug; 11(4):332-4. PubMed ID: 8878802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herd studies on coliform mastitis.
    Jasper DE; Dellinger JD; Bushnell RB
    J Am Vet Med Assoc; 1975 Apr; 166(8):778-80. PubMed ID: 804464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoradiography of cell wall-deficient variants of Proteus mirabilis in a rat kidney model.
    Hughes BF; Gomolka D
    Invest Urol; 1974 Mar; 11(5):357-60. PubMed ID: 4592926
    [No Abstract]   [Full Text] [Related]  

  • 25. Papillary necrosis in vitro: a scanning electron microscopic comparison of escherichia coli and Proteus mirabilis infection.
    Cohen MS; Davis CP; Baur PS; Warren MM
    Scan Electron Microsc; 1981; (Pt 3):65-72. PubMed ID: 7036330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of growth of Proteus mirabilis and Escherichia coli in urine in response to fasting and vegetarian diet.
    Kjeldsen-Kragh J; Kvaavik E; Bottolfs M; Lingaas E
    APMIS; 1995 Nov; 103(11):818-22. PubMed ID: 8546847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential susceptibility of Escherichia coli and Proteus mirabilis to mouse urine and to urea.
    Hadas H; Medalia O; Aronson M
    J Infect Dis; 1977 Jul; 136(1):100-3. PubMed ID: 18546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods.
    Kwiecińska-Piróg J; Bogiel T; Gospodarek E
    J Antibiot (Tokyo); 2013 Oct; 66(10):593-7. PubMed ID: 23801185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary virulence of Proteus mirabilis in two experimental mouse models.
    Peerbooms PG; Marian A; Verweij JJ; MacLaren DM
    Infect Immun; 1982 Jun; 36(3):1246-8. PubMed ID: 7047396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Bouzari S
    APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular immunity in pyelonephritis: inhibition of the spleen cell response to the mitogen concanavalin A.
    Williams TW; Friedlander AM; Lyons JM; Braude AI
    Cell Immunol; 1974 Oct; 14(1):33-8. PubMed ID: 4619354
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of a rat model for induction of pyelonephritis with cell wall deficiency variants of Proteus mirabilis.
    Hughes BF; Schwarz H; Gomolka D
    Invest Urol; 1972 Jul; 10(1):10-3. PubMed ID: 4556712
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antibiotic resistance of community-acquired uropathogenic Enterobacteriaceae isolated in Sfax (Tunisia)].
    Smaoui S; Abdelhedi K; Marouane C; Kammoun S; Messadi-Akrout F
    Med Mal Infect; 2015 Aug; 45(8):335-7. PubMed ID: 26362517
    [No Abstract]   [Full Text] [Related]  

  • 35. Growth-inhibiting metabolites of Proteus mirabilis.
    Grabow WO
    J Med Microbiol; 1972 May; 5(2):191-6. PubMed ID: 4555728
    [No Abstract]   [Full Text] [Related]  

  • 36. Antireflux ureteroileal anastomoses: two experimental technique.
    Starr A; Rose DH; Cooper JF; Snyder RN
    Invest Urol; 1974 Nov; 12(3):165-71. PubMed ID: 4613686
    [No Abstract]   [Full Text] [Related]  

  • 37. [Etiological study of experimental pyelonephritis--intrarenal bacterial behavior in an experimental model].
    Tadokoro H; Omori M
    Nihon Jinzo Gakkai Shi; 1974 Jun; 16(6):560-8. PubMed ID: 4619407
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experimental pyelonephritis from Proteus mirabilis L forms in rats].
    Toshkov A; Kuiumdzhiev A; Zakharieva S; Georgiev D; Gumpert I
    Acta Microbiol Virol Immunol (Sofiia); 1977; 6():42-8. PubMed ID: 343511
    [No Abstract]   [Full Text] [Related]  

  • 39. Studies on L forms of bacteria. In vitro induction and propagation.
    Abbate GF; Leonessa V; Altucci P
    Chemotherapy; 1973; 19(6):341-7. PubMed ID: 4603148
    [No Abstract]   [Full Text] [Related]  

  • 40. Proteus mirabilis infection in a mouse colony.
    Jones JB; Estes PC; Jordan AE
    J Am Vet Med Assoc; 1972 Sep; 161(6):661-4. PubMed ID: 4560278
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.